Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | Biomarker | disease | BEFREE | The cytocompatibility observed with normal human neuronal cells (HCN-1A) and the enhanced lethal effects in glioblastoma cells highlight the potential of PLGA-MOR-CTX nanoparticles as promising therapeutic nanocarriers towards GBM. | 31423502 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | Furthermore, knockdown of MALAT1 inhibited GBM proliferation and progression in vitro and reduced tumor volume and prolonged survival in an orthotopic GBM murine model. | 31648104 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | Together, these findings support MALAT1 as a target for chemosensitization of GBM and identify p50 and p52 as primary regulators of this ncRNA. | 30940658 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | In addition, silencing of MALAT1 clearly improved the sensitivity of GBM cells to chemotherapeutic agents including the current first-line therapy of GBM [temozolomide (TMZ)]. | 29202181 | 2018 | ||||
|
0.080 | Biomarker | disease | BEFREE | In conclusion, our study indicates that knockdown of MALAT1 reverses chemoresistance to TMZ via promoting miR-101 regulatory network in GBM and thus offers a novel prognostic marker and potential target for GBM TMZ-based chemotherapy. | 29479863 | 2018 | ||||
|
0.080 | AlteredExpression | disease | BEFREE | Moreover, high serum MALAT1 expression was associated with poor chemoresponse and survival in GBM patients receiving TMZ treatment. | 28187000 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | In the present study, whether MALAT1 contributes to the resistance of glioblastoma cell lines to temozolomide (TMZ) was investigated. | 28668966 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | Indeed, knockdown of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. | 25772239 | 2016 |